Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ALKS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAlkermes appoints Anne C. Whitaker as new independent director, expanding board to 11
Filed September 16, 2026 · Period ending September 14, 2026 · ~1 min read
Key Changes
-
medium
Board increased from 10 to 11 members and appointed Anne C. Whitaker as a new independent director, effective immediately, with term expiring at 2027 AGM.
Item 5.02 verify on EDGAR → -
medium
Whitaker brings CEO experience from Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals, plus senior commercial roles at Bausch Health, Sanofi, and GSK.
Exhibit 99 view on EDGAR → -
medium
She will receive a $600,000 initial equity award, split 50/50 between stock options and RSUs, vesting in three equal annual installments beginning one year after grant.
Item 5.02 verify on EDGAR → -
low
Whitaker currently serves on the boards of Basilea Pharmaceutica and ICON plc, indicating broad governance experience.
Exhibit 99 view on EDGAR → -
low
Company entered into standard indemnification agreements with Whitaker, consistent with previously filed forms.
Item 5.02 verify on EDGAR →
Summary
Alkermes plc announced the appointment of Anne C. Whitaker as a new independent director, effective immediately. The board expanded from 10 to 11 members to accommodate the addition. Whitaker brings extensive biopharmaceutical leadership experience, including CEO roles at Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals, as well as senior commercial positions at major pharmaceutical companies.
She also holds board seats at Basilea Pharmaceutica and ICON plc. As part of her compensation, Whitaker will receive an initial equity award valued at $600,000, split equally between stock options and restricted stock units, vesting over three years. The company also entered into standard indemnification agreements with her. This appointment appears to be a routine governance action to strengthen the board with an experienced industry executive, with no red flags identified in the filing.
Section-by-Section Diff
Event · Exhibit 99
Added in current filing · view on EDGAR →
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board).
The company added a new independent director to its board. Ms. Whitaker brings extensive commercial and operational experience from leadership roles at Aerami Therapeutics, Novoclem Therapeutics, Synta Pharmaceuticals, Bausch Health, Sanofi, and GlaxoSmithKline. She also serves on multiple public and private company boards.
Added in current filing · view on EDGAR →
Ms. Whitaker most recently served as chief executive officer of Aerami Therapeutics, a then clinical-stage biopharmaceutical company. Prior to Aerami, she served as chief executive officer of Novoclem Therapeutics, Inc. and Synta Pharmaceuticals Corporation.
The new director has prior CEO experience at three biopharmaceutical companies, which the company highlights as relevant to its strategic priorities. Her background includes senior commercial roles at large pharmaceutical firms.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Ms. Whitaker currently serves on the boards of directors of publicly-traded companies Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company and ICON plc, a healthcare intelligence and clinical research organization.
Ms. Whitaker holds board seats at two publicly traded companies and several private companies. This indicates broad governance experience but also potential time commitments across multiple boards.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company’s 2027 annual general meeting of shareholders.
The Board grew from 10 to 11 members and added Anne C. Whitaker as a new director. Her initial term runs until the 2027 annual general meeting. She has not yet been appointed to any Board committee.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 17, 2026 · How we verify